Table 1.
EBV latency protein | Type of latency | Biological activity | Associated cancersd |
---|---|---|---|
EBNA-1a | Latency I, II, III | Segregation of viral genome in progenies, DNA replication, inhibition of MHC class I, enhances p53 degradation | Burkitt lymphoma, Gastric cancer, Breast cancer |
EBNA-2 | Latency III | Upregulation of host and viral proteins (transactivation), facilitate B cell immortalization | Posttransplant lymphoproliferative disorder |
EBNA-3 | Latency III | Transcription transactivation of both host and viral proteins, immortalization of B cell | Posttransplant lymphoproliferative disorder |
EBNA-LPb | Latency III | Transactivation of EBNA-2 to inactivate tumor suppressors, essential for immortalization of B cells | Posttransplant lymphoproliferative disorder |
LMP-1/2c |
Latency II/III | B cell survival, upregulation of antiapoptotic proteins, mimics CD 40 ligand associated signaling, constitutively activate growth and cell survival promoting signaling pathways | Hodgkin lymphoma, Nasopharyngeal cancer, Posttransplant lymphoproliferative disorder, T/NK cell lymphoma, Breast cancer |
EBV-Micro RNAs | Latency I, II, III | Target host mRNAs involved in apoptosis, proliferation and transformation. Suppress antigen presentation and activation of immune cells | Gastric cancer, T/NK cell lymphoma, nasopharyngeal cancer |
a EBNA-1 is expressed and detected in all EBV associated malignancies. b EBNA-LP is also known as EBNA-5. c LMP-1/2 are both involved in epithelia and B cell tumors, however, LMP 2 is frequently detected in a majority of all tumors as compared to LMP-1. dThe associated tumors are not only limited to the ones discussed in this review.